Paper Review Records
All Paper Review Records
19 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
195
days
Formulation-Specific Safety Issues of HIV Pre-exposure Prophylaxis Drugs: A Disproportionality Analysis of the FAERS Database
Authors
Davide Rozza; Elisabetta Poluzzi; Ippazio Cosimo Antonazzo; Angela Boccia; Marco Paccini; Fortuna Gallucci; Domenico Ponticelli; Giulio Geraci; Fernando Agüero; Giampiero Mazzaglia; Lorenzo Giovanni Mantovani; Emanuel Raschi; Pietro FerraraShow moreShow less
Affiliations
1. Center for Public Health Research, University of Milan–Bicocca, Monza, Italy; 2. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 3. Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy; 4. Clinica Montevergine SpA, Mercogliano, Italy; 5. Department of Medicine and Surgery, “Kore” University of Enna, Enna, Italy; 6. Internal Medicine Unit, Hospital Umberto I, ASP Enna, Enna, Italy; 7. Preventive Medicine Unit, Hospital Universitari General de Catalunya, Quirónsalud, Barcelona, Spain; 8. Laboratory of Public Health, IRCCS Istituto Auxologico Italiano, Milan, ItalyShow moreShow less
258
days
Statin Use and Arterial Calcification in the General Population: A Longitudinal Analysis and a Negative Control Population
Authors
Mitra Nekouei Shahraki; Jeremy A Labrecque; Fariba Ahmadizar; Bruno H Stricker; Maryam Kavousi; Daniel BosShow moreShow less
Affiliations
1. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Department of Data Science and Biostatistics, Julius Global Health, University Medical Center Utrecht, Utrecht, The Netherlands; 3. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The NetherlandsShow moreShow less
173
days
Pharmacokinetics and Tolerability of Fexinidazole in Subjects with Hepatic Impairment
Authors
Matthieu Gassiot; Jean Pierre Beaucire; Sophie Hays; Sarah Lezzar; Céline Beauchard; Eric SultanShow moreShow less
Affiliations
1. Sanofi R&D, Montpellier, France; 2. Sanofi, Gentilly, France; 3. Biotrial, Rennes, France; 4. PhinC Development, Massy, France; 5. Foundation S, The Sanofi Collective, Gentilly, FranceShow moreShow less
179
days
Modeling Cancer Outcomes and Economic Impact of the Anti-PD-1/PD-L1 Immunotherapy in the Gulf: United Arab Emirates, Oman, and Kuwait
Authors
Humaid O. Al-Shamsi; Mohamed Farghaly; Ammar Abdaljalil; Abdulwahab Al-Tourah; Chana Saad; Youmna Bassil; Ghadah Albassam; Rami Nimer; Monika Naroz; Omar El-Badry; Rony AkelShow moreShow less
Affiliations
1. Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; 2. Dubai Health Insurance Corporation, Dubai, United Arab Emirates; 3. Sheikh Shakhboot Medical City, Abu Dhabi, United Arab Emirates; 4. Kuwait Cancer Control Center, Kuwait City, Kuwait; 5. Center of Clinical, Health Economics, and Outcomes Research (CCHO-FZ-LLC), Dubai, United Arab Emirates; 6. MSD KSA GmbH, Riyadh, Saudi Arabia; 7. MSD IDEA Middle East, Dubai, United Arab EmiratesShow moreShow less
190
days
Efficacy and Safety of Ustekinumab Biosimilars in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis
Authors
Mohsin Rashid; Awon Muhammad; Eeraj Saeed; Ali Akram Qureshi; Mohammad Maheer Mubashir; Mohammad Waqas bin Waheed; Muhammad Abdullah Yasin; Muhammad Abdullah; Ahsan Rashid; Zainab ZubairShow moreShow less
Affiliations
1. Department of Medicine, King Edward Medical University, Lahore, Pakistan; 2. Department of Medicine, District Headquarters Hospital, Jhelum, Pakistan; 3. Department of Medicine, Fatima Jinnah Medical University, Lahore, PakistanShow moreShow less
419
days
Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis: A Systematic Review
Authors
Mohammad Alimoradnori; Ali Abutorabi; Mozhdeh Zabihiyeganeh; Jalal Arabloo; Reza JahanghiriShow moreShow less
Affiliations
1. Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran; 2. Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran; 3. Department of Orthopedics, Bone and Joint Reconstruction Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; 4. Hospital Management Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, IranShow moreShow less
FAQ
How long does CLINICAL DRUG INVESTIGATION take to review a manuscript?
As of 2026-11-19, CrushSCI has 19 complete review records for CLINICAL DRUG INVESTIGATION. The fastest paper went from submission to acceptance in 15 days (Deuruxolitinib: New Approval, received 2026-04-29, accepted 2026-05-14); the slowest took 428 days. The average is 220.7 days and the median is 195 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
